Protein Misfolding Diseases and Therapeutic Approaches

被引:46
|
作者
Yadav, Kusum [1 ]
Yadav, Anurag [3 ]
Vashistha, Priyanka [1 ]
Pandey, Veda P. [1 ]
Dwivedi, Upendra N. [1 ,2 ]
机构
[1] Univ Lucknow, Dept Biochem, Lucknow, Uttar Pradesh, India
[2] Univ Lucknow, ONGC Ctr Adv Studies, Inst Dev Adv Comp, Lucknow, Uttar Pradesh, India
[3] Sardar Krushinagar Dantiwada Agr Univ, Coll Basic Sci & Humanities, Dept Microbiol, Banaskantha, Gujarat, India
关键词
Protein folding; protein misfolding; protein aggregation; molecular chaperones; pharmacological chaperones; protein misfolding diseases; TRANSMEMBRANE CONDUCTANCE REGULATOR; PHARMACOLOGICAL CHAPERONE THERAPY; NEPHROGENIC DIABETES-INSIPIDUS; ENZYME REPLACEMENT THERAPY; SPASTIC PARAPLEGIA SPG13; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; CHEMICAL CHAPERONES; ENDOPLASMIC-RETICULUM; CYSTIC-FIBROSIS;
D O I
10.2174/1389203720666190610092840
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein folding is the process by which a polypeptide chain acquires its functional, native 3D structure. Protein misfolding, on the other hand, is a process in which protein fails to fold into its native functional conformation. This misfolding of proteins may lead to precipitation of a number of serious diseases such as Cystic Fibrosis (CF), Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS) etc. Protein Quality-control (PQC) systems, consisting of molecular chaperones, proteases and regulatory factors, help in protein folding and prevent its aggregation. At the same time, PQC systems also do sorting and removal of improperly folded polypeptides. Among the major types of PQC systems involved in protein homeostasis are cytosolic, Endoplasmic Reticulum (ER) and mitochondrial ones. The cytosol PQC system includes a large number of component chaperones, such as Nascent-polypeptide-associated Complex (NAC), Hsp40, Hsp70, prefoldin and T Complex Protein-1 (TCP-1) Ring Complex (TRiC). Protein misfolding diseases caused due to defective cytosolic PQC system include diseases involving keratin/collagen proteins, cardiomyopathies, phenylketonuria, PD and ALS. The components of PQC system of Endoplasmic Reticulum (ER) include Binding immunoglobulin Protein (BiP), Calnexin (CNX), Calreticulin (CRT), Glucose-regulated Protein GRP94, the thiol-disulphide oxidoreductases, Protein Disulphide Isomerase (PDI) and ERp57. ER-linked misfolding diseases include CF and Familial Neurohypophyseal Diabetes Insipidus (FNDI). The components of mitochondrial PQC system include mitochondrial chaperones such as the Hsp70, the Hsp60/Hsp10 and a set of proteases having AAA+ domains similar to the proteasome that are situated in the matrix or the inner membrane. Protein misfolding diseases caused due to defective mitochondrial PQC system include medium-chain acyl-CoA dehydrogenase (MCAD)/Short-chain Acyl-CoA Dehydrogenase (SCAD) deficiency diseases, hereditary spastic paraplegia. Among therapeutic approaches towards the treatment of various protein misfolding diseases, chaperones have been suggested as potential therapeutic molecules for target based treatment. Chaperones have been advantageous because of their efficient entry and distribution inside the cells, including specific cellular compartments, in therapeutic concentrations. Based on the chemical nature of the chaperones used for therapeutic purposes, molecular, chemical and pharmacological classes of chaperones have been discussed.
引用
收藏
页码:1226 / 1245
页数:20
相关论文
共 50 条
  • [21] Proteomics in protein misfolding diseases
    Stoppini, Monica
    Obici, Laura
    Lavatelli, Francesca
    Giorgetti, Sofia
    Marchese, Loredana
    Moratti, Remigio
    Bellotti, Vittorio
    Merlini, Giampaolo
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2009, 47 (06) : 627 - 635
  • [22] Nanoimaging for protein misfolding diseases
    Lyubchenko, Yuri L.
    Kim, Bo-Hyun
    Krasnoslobodtsev, Alexey V.
    Yu, Junping
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2010, 2 (05) : 526 - 543
  • [23] Protein misfolding in neurodegenerative diseases
    Agorogiannis, EI
    Agorogiannis, GI
    Papadimitriou, A
    Hadjigeorgiou, GM
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2004, 30 (03) : 215 - 224
  • [24] Therapeutics for protein misfolding diseases
    Soto, C
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (20) : 2541 - 2542
  • [25] Nanomedicine and protein misfolding diseases
    Kransnoslobodtsev, Alexey V.
    Shlyakhtenko, Luda S.
    Ukraintsev, Egor
    Zaikova, Tatiana O.
    Keana, John F. W.
    Lyubchenko, Yuri L.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2005, 1 (04) : 300 - 305
  • [26] Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases
    Kelly, Jeffery W.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [27] Identification of potentially therapeutic short cyclic peptides against protein misfolding diseases
    Delivoria, Dafni Chrysanthi
    Linardaki, Zacharoula
    Matis, Ilias
    Bellou, Stamatia
    Pletsa, Vassiliki
    Skretas, Georgios
    FREE RADICAL BIOLOGY AND MEDICINE, 2017, 108 : S14 - S14
  • [28] Engineering bacteria for the discovery of potential therapeutic compounds against protein misfolding diseases
    Skretas, Georgios
    Delivoria, Dafni
    Matis, Ilias
    Papaevgeniou, Nikoletta
    Chondrogianni, Niki
    NEW BIOTECHNOLOGY, 2014, 31 : S12 - S13
  • [29] Inhibiting toxic aggregation of amyloidogenic proteins: A therapeutic strategy for protein misfolding diseases
    Cheng, Biao
    Gong, Hao
    Xiao, Hongwen
    Petersen, Robert B.
    Zheng, Ling
    Huang, Kun
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2013, 1830 (10): : 4860 - 4871
  • [30] Nanoimaging for protein misfolding and related diseases
    Lyubchenko, Yuri L.
    Sherman, Simon
    Shlyakhtenko, Luda S.
    Uversky, Vladimir N.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 99 (01) : 53 - 70